← Back to Search

PEMF Therapy for Postoperative Pain After Orthopedic Surgery

N/A
Recruiting
Led By Geoffrey D Abrams, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 days

Summary

This trial is testing whether PEMF therapy can help reduce pain in patients who have had shoulder or knee surgery. PEMF therapy uses electromagnetic waves to interact with the body's cells, which may reduce pain and speed up healing. The study will measure pain levels, medication use, and physical function after surgery. PEMF therapy has been evaluated as a therapeutic strategy for pain management in several clinical scenarios, showing positive efficacy and safety profiles.

Who is the study for?
This trial is for adults over 18 who are having shoulder or knee surgery and can do post-op physical therapy. They must not have taken NSAIDs a week before surgery, be willing to sign consent, and not drink excessively. Excluded are those with HIV, hepatitis, severe mental illness, certain connective tissue diseases, diabetes, unknown pain causes, recent corticosteroid use (except asthma/eye meds), medical marijuana users, compensation/litigation seekers for musculoskeletal issues.
What is being tested?
The study tests if PEMF therapy using Endonovo SofPulse reduces pain after orthopedic surgery on the shoulder or knee. It measures how much it lowers pain levels at day 10 post-surgery using a visual scale and checks medication usage and physical function outcomes.
What are the potential side effects?
The information provided does not specify side effects of PEMF therapy; however generally PEMF is considered non-invasive with minimal risks which may include mild discomfort or none at all.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean change from baseline in pain scores on the visual analog scale (VAS) at 10 days
Secondary study objectives
Mean change from baseline in narcotic pain medicine use at 10 days

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active PEMF GroupActive Control1 Intervention
Participants will have a 1 in 2 chance to get the active treatment device post-operatively. The device will be attached to the post-operative dressing. The device is an Endonovo SofPulse that emits a pulsed electromagnetic field (PEMF). Single blind randomization.
Group II: Placebo PEMF GroupPlacebo Group1 Intervention
Participants will have a 1 in 2 chance to get the placebo treatment device post-operatively. The device will be attached to the post-operative dressing. The Endonovo SofPulse placebo device does not emit a pulsed electromagnetic field (PEMF). Single blind randomization.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Pulsed Electromagnetic Field (PEMF) Therapy uses electromagnetic fields to reduce pain and inflammation by promoting cellular repair and improving blood flow, which can accelerate healing in shoulder injuries. Physical therapy, including exercises and manual techniques, helps restore mobility and strength by targeting the muscles and tendons around the shoulder. Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce inflammation and pain by inhibiting enzymes involved in the inflammatory process. Corticosteroid injections provide potent anti-inflammatory effects, offering relief from severe pain and swelling. These treatments are crucial for shoulder injury patients as they address pain, inflammation, and functional impairments, facilitating a quicker and more effective recovery.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,469 Previous Clinical Trials
17,501,671 Total Patients Enrolled
EndonovoUNKNOWN
Geoffrey D Abrams, MDPrincipal InvestigatorStanford University

Media Library

Active PEMF Group Clinical Trial Eligibility Overview. Trial Name: NCT04109638 — N/A
SLAP Tears Research Study Groups: Placebo PEMF Group, Active PEMF Group
SLAP Tears Clinical Trial 2023: Active PEMF Group Highlights & Side Effects. Trial Name: NCT04109638 — N/A
Active PEMF Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT04109638 — N/A
~3 spots leftby Feb 2025